Clinical trial
A Phase I/IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerabiity, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of [177Lu]-NeoB Administered in Patients With Advanced Solid Tumors Known to Overexpress Gastrin-releasing Peptide Receptor (GRPR)
NCT03872778 is registered in ClinicalTrials.gov with Advanced Accelerator Applications as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerabiity, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of [177Lu]-NeoB Administered in Patients With Advanced Solid Tumors Known to Overexpress Gastrin-releasing Peptide Receptor (GRPR)
- Lead sponsor
- Advanced Accelerator Applications
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 24, 2019
- Completion date
- November 27, 2025
- Enrollment
- 35 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.